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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus rhamnosus CNCM I-1720, Lactobacillus 
helveticus CNCM I-1722, Bifidobacterium longum subsp. longum 
CNCM I-3470 and Saccharomyces cerevisiae var. boulardii CNCM I-1079 
and defence against pathogenic gastro-intestinal microorganisms 
(ID 3017, further assessment) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006 in the framework of further assessment related to a combination of Lactobacillus rhamnosus 
CNCM I-1720, Lactobacillus helveticus CNCM I-1722, Bifidobacterium longum subsp. longum CNCM I-3470 
and Saccharomyces cerevisiae var. boulardii CNCM I-1079 and defence against pathogenic gastro-intestinal 
microorganisms. The food constituent that is the subject of the health claim, a combination of L. rhamnosus 
CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. 
boulardii CNCM I-1079, is sufficiently characterised. The claimed effect which is proposed for further 
assessment, defence against pathogenic gastro-intestinal microorganisms, is a beneficial physiological effect. 
The proposed target population is the general population. No human intervention studies which investigated the 
effect of a combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum 
CNCM I-3470 and S. cerevisiae var. boulardii CNCM I-1079 were provided. On the basis of the data 
presented, the Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. 
longum CNCM I-3470 and S. cerevisiae var. boulardii CNCM I-1079 and defence against pathogenic 
gastro-intestinal microorganisms.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA 
in order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of health claims in 
relation to a combination of Lactobacillus rhamnosus CNCM I-1720, Lactobacillus helveticus 
CNCM I-1722, Bifidobacterium longum subsp. longum CNCM I-3470 and Saccharomyces 
cerevisiae var. boulardii CNCM I-1079 and defence against pathogenic gastro-intestinal 
microorganisms. The scientific substantiation is based on the information provided by the competent 
Authority of France for further assessment of this claim. 
The food constituent that is the subject of the health claim is a combination of L. rhamnosus CNCM 
I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. 
boulardii CNCM I-1079. The Panel considers that the combination of L. rhamnosus CNCM I-1720, 
L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. 
boulardii CNCM I-1079 is sufficiently characterised.  
The claimed effect, which is proposed for further assessment, relates to defence against pathogenic 
gastro-intestinal microorganisms. The proposed target population is the general population. The 
Panel considers that defence against pathogenic gastro-intestinal microorganisms is a beneficial 
physiological effect. 
No human intervention studies which investigated the effect of a combination of L. rhamnosus 
CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and 
S. cerevisiae var. boulardii CNCM I-1079 were provided. The Panel considers that, in the absence 
of evidence for an effect of the combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM 
I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. boulardii CNCM I-1079 in 
humans, the studies provided on the effects of individual constituents cannot be used for 
substantiation of a claim on the combination. The Panel considers that no conclusions can be drawn 
from the references provided on the individual strains for the scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. rhamnosus CNCM I-1720, 
L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. 
boulardii CNCM I-1079 and defence against pathogenic gastro-intestinal microorganisms. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health 
claims would be eligible for further assessment by EFSA in order to be able to take a final decision 
on whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed 
effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 in 
which the Panel concluded that the data available were not sufficient to characterise a combination 
of Lactobacillus helveticus CNCM I-1722, Lactobacillus rhamnosus CNCM I-1720, 
Bifidobacterium longum CNCM I-3470 and Saccharomyces cerevisiae var. boulardii CNCM I-1079 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010), EFSA received additional 
information from the competent Authority of France for further assessment of this claim. The 
information provided in the framework of further assessment for the health claim which is the 
subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 3017)  
The food constituent that is the subject of the health claim is a combination of Lactobacillus 
rhamnosus CNCM I-1720, Lactobacillus helveticus CNCM I-1722, Bifidobacterium longum subsp. 
longum CNCM I-3470 and Saccharomyces cerevisiae var. boulardii CNCM I-1079. 
The formulation, which is the subject of the claim, contains the bacterial strains in a ratio of 1:1:1 in 
the form of lyophilised powders with a total amount of bacteria per capsule of 5 x 10
9
 CFU. The 
amount of S. cerevisiae var. boulardii is 125 mg (corresponding to 2.5 x10
9
 CFU) per capsule. 
The strain L. rhamnosus CNCM I-1720 is also known as L. rhamnosus R0011. A culture collection 
number from the French National Collection of Cultures of Microorganisms (CNCM I-1720) was 
provided. The CNCM is a restricted-access non-public collection which has the status of an 
International Depositary Authority under the Budapest Treaty. Data on the identification and 
characterisation of L. rhamnosus CNCM I-1720 at species and strain level, by using both phenotypic 
(cell morphology, colony morphology, carbohydrate fermentation pattern, enzymatic activity 
profile) and genotypic (DNA-DNA hybridisation, 16S rRNA gene sequence analysis, 16S/23S 
intergenic spacer region sequence analysis, strain-specific PCR, RAPD, PFGE) methods, were 
provided in the application for further assessment and in the accompanying references (Roy and 
Ward, 2004; Verdu et al., 2008; Yeung et al., 2002). The Panel considers that L. rhamnosus CNCM 
I-1720 is sufficiently characterised.  
The strain L. helveticus CNCM I-1722 is also known as L. helveticus R0052. A culture collection 
number from the CNCM, I-1722, was provided. Data on the identification and characterisation of 
L. helveticus CNCM I-1722 at species and strain level, by using both phenotypic (cell morphology, 
colony morphology, carbohydrate fermentation pattern, enzymatic activity profile) and genotypic 
(DNA-DNA hybridisation, 16S rRNA gene sequence analysis, 16S/23S intergenic spacer region 
sequence analysis, species-specific PCR, AFLP, MLST, RAPD, PFGE) methods, were provided in 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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the application for further assessment and in the accompanying references (Naser et al., 2006; Verdu 
et al., 2008). The Panel considers that L. helveticus CNCM I-1722 is sufficiently characterised.  
The strain B. longum subsp. longum CNCM I-3470 is also known as B. longum R0175. A culture 
collection number from the CNCM, I-3470, was provided. Data on the identification and 
characterisation of B. longum subsp. longum CNCM I-3470 at species and strain level, by using both 
phenotypic (cell morphology, colony morphology, carbohydrate fermentation pattern, enzymatic 
activity profile, antimicrobials resistance pattern) and genotypic (16S rRNA gene sequence analysis, 
elongation factor tuf gene sequence analysis, RAPD, PFGE) methods, were provided in the 
application for further assessment and in the accompanying references (Mattarelli et al., 2008). The 
Panel considers that B. longum subsp. longum CNCM I-3470 is sufficiently characterised. 
For S. cerevisiae var. boulardii CNCM I-1079 a culture collection number from the CNCM, I-1079, 
was provided. Data on phenotypic (morphological and biochemical analyses) and genotypic (RFLP 
analysis using a yeast DNA transposon probe for hybridisation, and PFGE and PCR delta sequence 
analysis) characterisation of S. cerevisiae var. boulardii CNCM I-1079 were provided in the 
application for further assessment. The Panel considers that S. cerevisiae var. boulardii CNCM 
I-1079 is sufficiently characterised. 
The Panel considers that the food constituent, a combination of L. rhamnosus CNCM I-1720, 
L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. 
boulardii CNCM I-1079, is sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 3017) 
The claimed effect, which is proposed for further assessment, refers to “helps to fight against 
gastro-intestinal (GI) pathogens”. The proposed target population is the general population. 
The presence of pathogenic micro-organisms in the gastro-intestinal tract (e.g. viruses and bacteria) 
may lead to the development of gastro-intestinal infections. Defence against pathogenic 
gastro-intestinal microorganisms may protect against the development of gastro-intestinal infections. 
The Panel considers that defence against pathogenic gastro-intestinal microorganisms is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect (ID 3017) 
The references provided in relation to this claim included human intervention studies, 
meta-analyses, animal studies, in vitro studies, publications on characterisation aspects and one 
review paper.  
The human, animal or in vitro studies provided investigated the effects of S. cerevisiae var. 
boulardii, the effects of individual bacterial strains or pairs of bacterial strains, which are part of the 
food constituent that is the subject of the claim, or combinations of microorganisms other than the 
combination of strains that is the subject of the claim.  
No human intervention studies which investigated the effect of a combination of L. rhamnosus 
CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 and 
S.cerevisiae var. boulardii CNCM I-1079 were provided. 
The Panel considers that, in the absence of evidence for an effect of the combination of 
L. rhamnosus CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. longum CNCM I-3470 
and S. cerevisiae var. boulardii CNCM I-1079 in humans, the studies on the effects of individual 
constituents provided cannot be used for substantiation of a claim on the combination. The Panel 
A combination of bacterial strains and defence against pathogenic  
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considers that no conclusions can be drawn from the references provided on the individual strains 
for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM I-1722, 
B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. boulardii CNCM I-1079 and defence 
against pathogenic gastro-intestinal microorganisms. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM 
I-1722, B. longum subsp. longum CNCM I-3470 and S. cerevisiae var. boulardii CNCM 
I-1079, which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed for further assessment relates to defence against pathogenic 
gastro-intestinal microorganisms. The proposed target population is the general population. 
Defence against pathogenic gastro-intestinal microorganisms is a beneficial physiological 
effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. rhamnosus CNCM I-1720, L. helveticus CNCM I-1722, B. longum subsp. 
longum CNCM I-3470 and S. cerevisiae var. boulardii CNCM I-1079 and defence against 
pathogenic gastro-intestinal microorganisms. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00205). The scientific substantiation is based on the information provided by 
the competent Authority of France for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's 
development and health. This Community list shall be adopted through the Regulatory Committee 
procedure and following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food 
many health claims may therefore be scientifically true. Therefore, the relative importance of food 
e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: 
for functions affected by a large number of dietary factors it should be considered whether a 
reference to a single food is scientifically pertinent.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. 
Claims should be scientifically substantiated by taking into account the totality of the available 
scientific data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and 
the claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of 
the target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional 
or physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment 
whether such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between 
the food and the function. This may be due to commercial practices, consumer perception and 
linguistic or cultural differences across the EU. Nevertheless, the wording used to make health 
claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 
3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient 
or other substance in growth, development and the functions of the body". Therefore, the 
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requirement to describe or refer to the 'role' of a nutrient or substance in growth, development and 
the functions of the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different 
relationships between the various foods and health. It is not the intention of the regulator to adopt a 
detailed and rigid list of claims where all possible wordings for the different claims are approved. 
Therefore, it is not required that EFSA comments on each individual wording for each claim unless 
the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may 
consider and comment generally on such elements relating to wording to ensure the compliance with 
the criteria laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific 
data, and by weighing the evidence. In this context EFSA is invited to comment on the 
nature and quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and 
the claimed effect in humans and whether the magnitude of the effect is related to the 
quantity consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of 
a balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the 
marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether 
the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions 
of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to a combination of Lactobacillus rhamnosus CNCM I-1720, 
Lactobacillus helveticus CNCM I-1722, Bifidobacterium longum subsp. longum CNCM I-3470 and 
Saccharomyces cerevisiae var. boulardii CNCM I-1079, including conditions of use, as proposed in 
the framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
3017 A combination of 
Lactobacillus rhamnosus 
CNCM I-1720, Lactobacillus 
helveticus CNCM I-1722, 
Bifidobacterium longum 
subsp. longum CNCM I-3470 
and Saccharomyces boulardii 
CNCM I-1079 
The food constituent helps to 
fight against gastro-intestinal 
(GI) pathogens. The presence 
of pathogenic microorganisms 
in the GI tract may lead to the 
development of GI infections 
like diarrhea from different 
etiology (antibiotic associated 
diarrhea, traveller’s diarrhea, 
acute diarrhea). Indeed, 
antibiotic treatments, change 
in dietary habits when 
travelling, or hospitalization 
can lead to GI infections 
accompanied with diarrheas. 
Defence against gastro-
intestinal pathogens 
Conditions of use 
The recommended dosage is two to four capsules per day. Each capsule contains 5*109 CFU of 
bacteria and 125 mg of Saccharomyces boulardii (corresponding to 2.5*109 CFU at 
manufacturing). 
To reinforce the intestine against intestinal traveller’s disorders, take for three to five days before 
departure and while away. 
General population, including travellers to developing countries, who are a high risk population 
for the development of diarrhoea (traveller’s diarrhoea mainly caused by bacteria; E. coli is the 
pathogen most frequently isolated). 
The percentage of each bacteria strain is 33.3%, under the form of lyophilised powders (total 
amount of bacteria is 5*109 CFU per capsule). The amount of Saccharomyces boulardii is 125 
mg per capsule (corresponding to 2.5*109 CFU at manufacturing).  
The finished product is commercialised as a capsule under the brand name Protecflor. 
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GLOSSARY AND ABBREVIATIONS 
AFLP   Amplified fragment length polymorphism 
CFU   Colony forming units 
CNCM   Collection Nationale de Cultures de Microorganismes, France 
DNA   Deoxyribonucleic acid  
MLST   Multi-locus sequence typing 
PCR   Polymerase chain reaction 
PFGE   Pulsed field gel electrophoresis 
RAPD   Randomly amplified polymorphic DNA 
RNA   Ribonucleic acid  
 
